services
Investor & Portfolio Advisory
Independent physician-led diligence for medtech, diagnostics, digital health, and AI investments, focused on the clinical, regulatory, evidence, adoption, and execution risks a financial model may not reveal.
" What a Physician Sees That a Financial Model Can't "
THE PROBLEM
Where healthcare innovations lose their footing
Healthcare investments can look compelling financially while important assumptions remain untested clinically.
A technology may address a real market opportunity yet still face weak clinical relevance, evidence limitations, regulatory uncertainty, workflow barriers, unrealistic adoption assumptions, or an execution plan that depends on too many things going right.
RNB Ventures helps investors and boards pressure-test those assumptions before capital is committed, and helps portfolio companies address vulnerabilities that could affect value creation after investment. RNB does not replace financial, legal, or regulatory diligence. We add the independent clinical and strategic perspective needed to determine whether the healthcare story actually holds together.
WHAT'S INCLUDED
How the engagement helps
Clinical & Evidence Diligence
Does the technology solve a clinically meaningful problem, and does the evidence support the promise?
Adoption & Workflow Assessment
Will clinicians actually use it? Can organizations operationalize it? Who buys, pays, benefits, and potentially blocks adoption?
Management Assumption Stress-Test
Challenge the assumptions underlying timelines, clinical milestones, regulatory strategy, differentiation, adoption, and commercialization.
Portfolio-Company Advisory
Help portfolio leadership address strategic vulnerabilities uncovered through diligence and prepare for critical milestones.
Regulatory & Claims Assessment
Are intended use, development strategy, likely labeling, evidence, and commercial expectations aligned?
Digital Health & AI Assessment
Evaluate clinical utility, algorithm-development assumptions, validation strategy, intended use, workflow integration, generalizability, and whether performance metrics translate into meaningful clinical value.
Board & Investment Committee Support
Provide an independent physician-executive perspective before major investment, financing, development, partnership, or commercialization decisions.
Investment risk in healthcare is often hidden inside an assumption, not a spreadsheet. RNB pressure-tests whether the clinical need, evidence, regulatory pathway, workflow, adoption logic, and management assumptions support the investment thesis.
WHO IT'S FOR
Who this serves
Primary: medtech investors and corporate venture groups, diagnostics and IVD investors, boards and investment committees, and medtech and diagnostics portfolio companies. Expanding areas: digital-health investors and companies, AI-enabled healthcare technologies, and algorithm-based diagnostics and clinical decision-support technologies.
Proof
Credentials behind the work
Robert N. Bilkovski, MD, MBA brings investor diligence experience from inside global healthcare organizations as well as more than two decades of clinical and healthcare-industry leadership. Relevant experience includes due-diligence experience in pharmaceutical business development and with GE Ventures; more than 30 clinical trials across medical devices, diagnostics, and pharmaceuticals; former medical leadership at Abbott, GE Healthcare, and Hospira/Pfizer; current and prior CMO / fractional executive leadership; and experience across clinical development, regulatory strategy, evidence, product risk, adoption, commercialization, and healthcare AI/algorithms.
QUESTIONS
Frequently asked
Can RNB evaluate digital-health and AI-enabled healthcare companies?
Yes. RNB can evaluate whether an algorithm or digital-health technology addresses a meaningful clinical problem, whether its development and validation strategy support the intended use, how performance translates into real-world clinical utility, and whether workflow, regulatory, adoption, and commercialization assumptions are credible.
How is this different from financial or regulatory diligence?
RNB does not replace financial, legal, or regulatory diligence. We add the independent clinical and strategic perspective needed to determine whether the healthcare story actually holds together.
When is clinical diligence most valuable?
Before capital is committed, and when portfolio companies are approaching critical clinical, regulatory, financing, partnership, or commercialization milestones.